391 related articles for article (PubMed ID: 32232912)
1. Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma.
Deng C; Xu Y; Fu J; Zhu X; Chen H; Xu H; Wang G; Song Y; Song G; Lu J; Liu R; Tang Q; Huang W; Wang J
Cancer Sci; 2020 Jun; 111(6):1899-1909. PubMed ID: 32232912
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma.
Trieb K; Lechleitner T; Lang S; Windhager R; Kotz R; Dirnhofer S
Pathol Res Pract; 1998; 194(10):679-84. PubMed ID: 9820863
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions.
Toda Y; Kohashi K; Yamada Y; Yoshimoto M; Ishihara S; Ito Y; Iwasaki T; Yamamoto H; Matsumoto Y; Nakashima Y; Mawatari M; Oda Y
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2607-2620. PubMed ID: 32388585
[TBL] [Abstract][Full Text] [Related]
4. Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.
Ligon JA; Choi W; Cojocaru G; Fu W; Hsiue EH; Oke TF; Siegel N; Fong MH; Ladle B; Pratilas CA; Morris CD; Levin A; Rhee DS; Meyer CF; Tam AJ; Blosser R; Thompson ED; Suru A; McConkey D; Housseau F; Anders R; Pardoll DM; Llosa N
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021032
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.
Li F; Zhao Y; Wei L; Li S; Liu J
Cancer Biol Ther; 2018 Aug; 19(8):695-705. PubMed ID: 29621426
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.
Lo CS; Sanii S; Kroeger DR; Milne K; Talhouk A; Chiu DS; Rahimi K; Shaw PA; Clarke BA; Nelson BH
Clin Cancer Res; 2017 Feb; 23(4):925-934. PubMed ID: 27601594
[No Abstract] [Full Text] [Related]
7. A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma.
Yang H; Zhao L; Zhang Y; Li FF
Cancer Med; 2021 Aug; 10(16):5696-5711. PubMed ID: 34258887
[TBL] [Abstract][Full Text] [Related]
8. SDF-1/CXCR4 axis facilitates myeloid-derived suppressor cells accumulation in osteosarcoma microenvironment and blunts the response to anti-PD-1 therapy.
Jiang K; Li J; Zhang J; Wang L; Zhang Q; Ge J; Guo Y; Wang B; Huang Y; Yang T; Hao D; Shan L
Int Immunopharmacol; 2019 Oct; 75():105818. PubMed ID: 31437795
[TBL] [Abstract][Full Text] [Related]
9. Tumor-infiltrating lymphocytes as a feasible adjuvant immunotherapy for osteosarcoma with a poor response to neoadjuvant chemotherapy.
Shi J; Li M; Yang R
Immunotherapy; 2020 Jun; 12(9):641-652. PubMed ID: 32489121
[No Abstract] [Full Text] [Related]
10. Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer.
Zhang Y; Yu M; Jing Y; Cheng J; Zhang C; Cheng L; Lu H; Cai MC; Wu J; Wang W; Lou W; Qiu L; Tan L; Lu H; Yin X; Zhuang G; Di W
Br J Cancer; 2021 Jan; 124(2):414-424. PubMed ID: 33087896
[TBL] [Abstract][Full Text] [Related]
11. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
Sundara YT; Kostine M; Cleven AH; Bovée JV; Schilham MW; Cleton-Jansen AM
Cancer Immunol Immunother; 2017 Jan; 66(1):119-128. PubMed ID: 27853827
[TBL] [Abstract][Full Text] [Related]
12. The tumor immune microenvironment and immune-related signature predict the chemotherapy response in patients with osteosarcoma.
He L; Yang H; Huang J
BMC Cancer; 2021 May; 21(1):581. PubMed ID: 34016089
[TBL] [Abstract][Full Text] [Related]
13. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma.
Zhang C; Zheng JH; Lin ZH; Lv HY; Ye ZM; Chen YP; Zhang XY
Aging (Albany NY); 2020 Feb; 12(4):3486-3501. PubMed ID: 32039832
[TBL] [Abstract][Full Text] [Related]
14. Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype.
Force J; Howie LJ; Abbott SE; Bentley R; Marcom PK; Kimmick G; Westbrook K; Sammons SL; Parks M; Topping DL; Emerson R; Broadwater G; Hyslop T; Blackwell KL; Nair SK
Clin Breast Cancer; 2018 Oct; 18(5):410-417. PubMed ID: 29615305
[TBL] [Abstract][Full Text] [Related]
15. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma.
Koirala P; Roth ME; Gill J; Piperdi S; Chinai JM; Geller DS; Hoang BH; Park A; Fremed MA; Zang X; Gorlick R
Sci Rep; 2016 Jul; 6():30093. PubMed ID: 27456063
[TBL] [Abstract][Full Text] [Related]
16. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant cisplatin and paclitaxel modulate tumor-infiltrating T cells in patients with cervical cancer.
Heeren AM; van Luijk IF; Lakeman J; Pocorni N; Kole J; de Menezes RX; Kenter GG; Bosse T; de Kroon CD; Jordanova ES
Cancer Immunol Immunother; 2019 Nov; 68(11):1759-1767. PubMed ID: 31616965
[TBL] [Abstract][Full Text] [Related]
18. Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial.
Li X; Warren S; Pelekanou V; Wali V; Cesano A; Liu M; Danaher P; Elliott N; Nahleh ZA; Hayes DF; Hortobagyi GN; Barlow WE; Hatzis C; Pusztai L
J Immunother Cancer; 2019 Apr; 7(1):88. PubMed ID: 30967156
[TBL] [Abstract][Full Text] [Related]
19. Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors.
Ratti C; Botti L; Cancila V; Galvan S; Torselli I; Garofalo C; Manara MC; Bongiovanni L; Valenti CF; Burocchi A; Parenza M; Cappetti B; Sangaletti S; Tripodo C; Scotlandi K; Colombo MP; Chiodoni C
Clin Cancer Res; 2017 Sep; 23(17):5149-5161. PubMed ID: 28600479
[No Abstract] [Full Text] [Related]
20. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]